The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands of percent.

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.

According to the Federal Trade Commission, UnitedHealth Group has been charging patients markups on lifesaving drugs. Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their prices by hundreds — and in some cases,

FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts

The updated tally extends the scope beyond what was previously described by company Chief Executive Andrew Witty.

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.

UnitedHealth reported fourth-quarter results on Thursday that reflected persistent challenges for the health insurance sector.

Your medical data is not as safe as you think. Discover how a massive ransomware attack exposed millions and the key steps to protect your privacy now.

(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly ... organ transplants and other conditions and procedures, the FTC said. The report demonstrates how pharmacy benefit managers influence every aspect ...

UnitedHealth Group has reported quarterly profits of $5.5 billion after tax in its first earnings release since the killing of UnitedHealthcare CEO Brian Thompson in New York City, which sparked a wider debate about the cost of health insurance and medication for the American public.

and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) accused their pharmacy benefit manager units of imposing significant price markups on specialty ...

The City of Greensboro, North Carolina, which provides public safety, emergency, and health services to over 300,000 residents and spends millions annually on insulin medications, filed a lawsuit last